With respect to clinical data, we analyzed the relationship between SMYD3 expression levels and breast cancer prognosis using the TCGA database and observed that there was no significant association between SMYD3 expression and progression‐free survival (PFS) or OS (Figure S12E, Supporting Information). Here, SMYD3 is linked to breast carcinoma.